ADMET screening is crucial to the drug development process and assists the elimination rate of weak drug candidates early in the drug-discovery process, and decreases the proportion of compounds failing in clinical trials for ADMET reasons. SAE Media Group's 5th Annual ADMET Conference will bring you up to date with the latest developments, technologies and techniques that are in use across the industry and look towards the future.
By attending this conference, you will learn:
- How to effectively integrate ADMET optimisation into drug discovery to reduce attrition rates from AstraZeneca
- Strategies for predicting drug-drug interactions arising from CYP450 inhibition from Pfizer
- How to develop a mechanism-based PK/PD model from Eli Lilly
- The application of High Content Analysis for predictive cytotoxicity testing & preclinical toxicity biomarkers from University College Dublin
- Tools and strategies to consider in characterising and investigating hepatotoxicity from Genetech
- What the emerging in vitro toxicity assays are and the role of stem cells in assessing human toxicology from Roche
- Case studies demonstrating the benefits of evaluating PK in early stage drug development from Merck
The conference will provide a look at how the big names in the pharma industry are approaching ADMET. With a case study focus and presentations from companies including Novartis, AstraZeneca, Pfizer, Eli Lilly, Genentech, MSD, Merck & Co., Roche, Gedeon Richter and more along with distinguished representatives from top academic organisations this conference promises to provide an intimate environment for benchmarking against industry leaders and networking.
Featured Presentations:
- Building hypotheses in lead selection and optimisation
Bernard Faller, Director of Metabolism & Pharmacokinetics / in-vitro ADME, Novartis, Switzerland
- ADME Optimisation in Early- and Late-Phase Drug Discovery
Gerhard Gross, Global Discipline Leader ADME, AstraZeneca, UK
- In Vitro and In Vivo Approaches for Assessing the Potential for Drug Induced Liver Injury
Donna Dambach, Director, Investigative Safety Assessment, Genentech, USA
- Emerging In Vitro Toxicity Assays and the Role of Stem Cells in Assessing Human Toxicology
Claudia McGinnis, Group Head, In Vitro Toxicology, Roche, Switzerland
For speaker opportunities, contact SAE Media Groupproduction@SAE Media Group-online.co.uk
For sponsorship and exhibitioning opportunities, contact sponsorshipdept@SAE Media Group-online.co.uk
Bernard Faller
Director of Metabolism & Pharmacokinetics / in-vitro ADME
Novartis
Donna Dambach
Director, Investigative Safety Assessment
Genentech
Gerhard Gross
Global Discipline Leader ADME
AstraZeneca
Claudia McGinnis
Group Head, In Vitro Toxicology
Roche
Willem Schoonen
Senior Research Scientist, Toxicology & Drug Disposition
MSD
Punam Sandhu
Senior Investigator
Merck
Kuresh Youdim
Senior Principal Scientist
Pfizer
Richard Weaver
Associate Principal Scientist
AstraZeneca
See the full lineup...
|
|